METHODS AND COMPOSITIONS RELATED TO ANTIBODY FRAGMENTS THAT BIND TO TUMOR-ASSOCIATED GLYCOPROTEIN 72 (TAG-72)
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 23, 2024
app pub date -
Aug 9, 2023
filing date -
Jul 23, 2014
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Antibodies recognizing TAG-72 provide a novel approach for the imaging, detection, and treatment of cancer. These methods are made possible by using antibody fragments that bind specifically to the sialyl-Tn surface adhesin of TAG-72. Antibody fragment derivatives are advantageously useful over other antibody and antibody fragments known in the art because they are easy to express in large quantities, can penetrate tissues easily and lack the constant domains that promote often unwanted and usually superfluous effector functions.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully